| Adam Criss, DO | |
|
1999 Marcus Ave, Suite 216, New Hyde Park, NY 11042-1017 | |
| (516) 775-4545 | |
| (516) 775-4646 |
| Full Name | Adam Criss |
|---|---|
| Gender | Male |
| Speciality | Nephrology |
| Experience | 27 Years |
| Location | 1999 Marcus Ave, New Hyde Park, New York |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386742039 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RN0300X | Internal Medicine - Nephrology | 216967 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| New Hyde Park Dialysis Center | New hyde park, NY | Dialysis facility |
| Garden City Dialysis Center | Garden city, NY | Dialysis facility |
| Catholic Home Care | Farmingdale, NY | Home health agency |
| North Shore Home Care Chha | Westbury, NY | Home health agency |
| St Francis Hospital - The Heart Center | Roslyn, NY | Hospital |
| North Shore University Hospital | Manhasset, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Optum Medical Care Pc | 9931013240 | 997 |
News Archive
Shire plc, the global specialty biopharmaceutical company, today presented positive top line results of the first European phase III study of once-daily lisdexamfetamine dimesylate (LDX) in children and adolescents aged 6 to 17 years with Attention-Deficit/Hyperactivity Disorder.
Human Genome Sciences, Inc. announced today a license agreement with DakoCytomation A/S (Glostrup, Denmark), under which DakoCytomation has acquired exclusive worldwide rights to develop and commercialize pharmacogenomic diagnostic tests in the field of oncology based on the TRAIL Receptor-1 (TRAIL-R1) and TRAIL Receptor-2 (TRAIL-R2) proteins.
Apricus Biosciences, Inc., today announced data from animal studies showing that the NexACT technology significantly improved the oral delivery of five small molecule drugs tested, with the best improvements up to 20-fold, in terms of improvement in absorption.
NYU College of Dentistry's Department of Pediatric Dentistry has received a nearly $2 million grant from the Health Resources and Services Administration to train dentists and other health professionals to provide oral health care to people with disabilities and complex medical conditions.
› Verified 5 days ago
| Entity Name | Optum Medical Care Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1982643003 PECOS PAC ID: 9931013240 Enrollment ID: O20031119000321 |
News Archive
Shire plc, the global specialty biopharmaceutical company, today presented positive top line results of the first European phase III study of once-daily lisdexamfetamine dimesylate (LDX) in children and adolescents aged 6 to 17 years with Attention-Deficit/Hyperactivity Disorder.
Human Genome Sciences, Inc. announced today a license agreement with DakoCytomation A/S (Glostrup, Denmark), under which DakoCytomation has acquired exclusive worldwide rights to develop and commercialize pharmacogenomic diagnostic tests in the field of oncology based on the TRAIL Receptor-1 (TRAIL-R1) and TRAIL Receptor-2 (TRAIL-R2) proteins.
Apricus Biosciences, Inc., today announced data from animal studies showing that the NexACT technology significantly improved the oral delivery of five small molecule drugs tested, with the best improvements up to 20-fold, in terms of improvement in absorption.
NYU College of Dentistry's Department of Pediatric Dentistry has received a nearly $2 million grant from the Health Resources and Services Administration to train dentists and other health professionals to provide oral health care to people with disabilities and complex medical conditions.
› Verified 5 days ago
| Entity Name | Prohealth Care Associates Llp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275596280 PECOS PAC ID: 4486544186 Enrollment ID: O20040317000468 |
News Archive
Shire plc, the global specialty biopharmaceutical company, today presented positive top line results of the first European phase III study of once-daily lisdexamfetamine dimesylate (LDX) in children and adolescents aged 6 to 17 years with Attention-Deficit/Hyperactivity Disorder.
Human Genome Sciences, Inc. announced today a license agreement with DakoCytomation A/S (Glostrup, Denmark), under which DakoCytomation has acquired exclusive worldwide rights to develop and commercialize pharmacogenomic diagnostic tests in the field of oncology based on the TRAIL Receptor-1 (TRAIL-R1) and TRAIL Receptor-2 (TRAIL-R2) proteins.
Apricus Biosciences, Inc., today announced data from animal studies showing that the NexACT technology significantly improved the oral delivery of five small molecule drugs tested, with the best improvements up to 20-fold, in terms of improvement in absorption.
NYU College of Dentistry's Department of Pediatric Dentistry has received a nearly $2 million grant from the Health Resources and Services Administration to train dentists and other health professionals to provide oral health care to people with disabilities and complex medical conditions.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Adam Criss, DO 1999 Marcus Ave, Suite 216, New Hyde Park, NY 11042-1017 Ph: (516) 775-4545 | Adam Criss, DO 1999 Marcus Ave, Suite 216, New Hyde Park, NY 11042-1017 Ph: (516) 775-4545 |
News Archive
Shire plc, the global specialty biopharmaceutical company, today presented positive top line results of the first European phase III study of once-daily lisdexamfetamine dimesylate (LDX) in children and adolescents aged 6 to 17 years with Attention-Deficit/Hyperactivity Disorder.
Human Genome Sciences, Inc. announced today a license agreement with DakoCytomation A/S (Glostrup, Denmark), under which DakoCytomation has acquired exclusive worldwide rights to develop and commercialize pharmacogenomic diagnostic tests in the field of oncology based on the TRAIL Receptor-1 (TRAIL-R1) and TRAIL Receptor-2 (TRAIL-R2) proteins.
Apricus Biosciences, Inc., today announced data from animal studies showing that the NexACT technology significantly improved the oral delivery of five small molecule drugs tested, with the best improvements up to 20-fold, in terms of improvement in absorption.
NYU College of Dentistry's Department of Pediatric Dentistry has received a nearly $2 million grant from the Health Resources and Services Administration to train dentists and other health professionals to provide oral health care to people with disabilities and complex medical conditions.
› Verified 5 days ago
Dr. Farheen Hasan, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 27005 76th Ave, New Hyde Park, NY 11040 Phone: 718-470-7000 | |
Carylann Hadjiyane, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 1991 Marcus Ave, Suite 101, New Hyde Park, NY 11042 Phone: 516-365-4949 Fax: 516-365-5462 | |
Paul S. Berg, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 2001 Marcus Ave, Suite N204, New Hyde Park, NY 11042 Phone: 516-684-9229 Fax: 516-977-8589 | |
Dr. Michael Jason Levine, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 1999 Marcus Ave Ste 220, New Hyde Park, NY 11042 Phone: 516-869-5400 Fax: 516-869-5800 | |
Gisele Wolf-klein, MD Nephrology Medicare: Medicare Enrolled Practice Location: 2800 Marcus Ave, Suite 200, New Hyde Park, NY 11042 Phone: 516-708-2522 Fax: 516-708-2570 | |
Dr. Monty Max Bodenheimer, MD Nephrology Medicare: Not Enrolled in Medicare Practice Location: 3003 New Hyde Park Rd, Ste 406, New Hyde Park, NY 11042 Phone: 516-719-0102 Fax: 516-358-5403 | |
Michael Xin Chen, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 27005 76th Ave, New Hyde Park, NY 11040 Phone: 718-470-3377 |